Skip to main
  1. Stocks
  2. TScan Therapeutics
  3. Forecast
TCRX

TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics (TCRX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

TScan Therapeutics is supported by encouraging Cohort C clinical data, as all 13 patients achieved complete donor chimerism by August 27th, including two previously relapsed patients who responded after a third dose of TSC-101 and/or maintenance therapy. The 6-month relapse rate of about 20% in 14 patients, most of whom were MRD+, compares favorably with historic relapse rates of roughly 45% in MRD+ and 20% in MRD- patients after HSCT, strengthening the case that its TCR-T approach may meaningfully reduce post-transplant relapse risk. With an update planned for ASH in 4Q:26 and a ≥1-year update for all patients, including the 7 patients from ALLOHA-2, in 2Q:27, the company has multiple upcoming catalysts that could validate the durability of its program.

Bears say

TScan Therapeutics is facing a thesis-breaking shift because management paused its most advanced asset, TSC-101 in ALLOHA-2, despite encouraging Cohort C data and complete donor chimerism, removing the main clinical and valuation driver. The company is now reliant on two preclinical in vivo TCR-T programs targeting PRAME and MAGE-A4, with first IND expectations in 3Q27 and Phase 1 not planned until 4Q27, while the 75% workforce reduction and elimination of internal manufacturing only extend runway to 4Q27. Although the restructuring is expected to create about $55M of cumulative savings and leave $100M of 2Q:26 cash to fund operations into 4Q27, the stock remains burdened by financing risk, partnership dependence, and limited visibility that the new platform can generate near-term value.

TScan Therapeutics (TCRX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TScan Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

TScan Therapeutics (TCRX) Analyst Forecast & Price Prediction

Get the latest TScan Therapeutics (TCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TScan Therapeutics (TCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TScan Therapeutics (TCRX) Forecast

Analysts have given TScan Therapeutics (TCRX) a Buy based on their latest research and market trends.

According to 3 analysts, TScan Therapeutics (TCRX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TScan Therapeutics (TCRX)


TScan Therapeutics (TCRX) Analyst Forecast & Price Prediction

Get the latest TScan Therapeutics (TCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TScan Therapeutics (TCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TCRX stock data and trends